Preprint · CC-BY
via OpenAlex
Balancing the promise and risks of geroscience
Alan Arthur Cohen, John Beard, Luigi Ferrucci, Tamàs Fülöp, Vadim N. Gladyshev, Mahdi Moqri, Marcel G. M. Olde Rikkert, Martin A. Picard
· 2024 · ▲ 2 citations
Abstract
The geroscience hypothesis – that by intervening on the basic biological mechanisms of aging we could simultaneously reduce the risks of many chronic diseases and dramatically improve healthspan(definition) – has garnered substantial traction and enthusiasm in the past decade. And indeed, if successful, there is enormous potential to reduce the burden of disease in human populations. However, there are also reasons to be cautious, and these have received substantially less attention. Aging differs from traditional disease targets in a number of ways: (1) it is hard to define; (2) the biology of aging has likely been carefully calibrated by natural selection to balance multiple trade-offs, which are still poorly understood; (3) interventions may need to start decades before all benefits and harms are apparent; and (4) it is hard to disambiguate the cumulative effects of poor lifestyles from aging, but interventions for the two could be different. Together, these challenges, and the complex and interdependent nature of the underlying biology, mean that interventions that result in improvements in function or for certain biomarkers of aging and appear beneficial in the short term might still have a substantial chance of being harmful in the long-term, particularly if the interventions are acting on mechanisms that trade off short-term benefits for long-term harms. While some such risk is present in any medical intervention, we believe it is particularly pronounced for aging biology because the mechanisms targeted tend to be fundamental mechanisms of cell biology that may pervasively affect the whole organism. We propose a number of solutions – hallmarks to guide geroscience interventions – that should help minimize these risks while helping make progress.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.31219/osf.io/uf25z
- Canonical
- link ↗
- Fetched
- 2026-10-23 MST
Cite this
APA
Cohen, A.A., Beard, J., Ferrucci, L., Fülöp, T., Gladyshev, V.N., Moqri, M., Rikkert, M.G.M.O., & Picard, M.A. (2024). Balancing the promise and risks of geroscience. https://doi.org/10.31219/osf.io/uf25z
Vancouver
Cohen AA, Beard J, Ferrucci L, Fülöp T, Gladyshev VN, Moqri M, et al. Balancing the promise and risks of geroscience. 2024. doi:10.31219/osf.io/uf25z.
BibTeX
@unpublished{alan2024Balanc,
title = {Balancing the promise and risks of geroscience},
author = {Alan Arthur Cohen and John Beard and Luigi Ferrucci and Tamàs Fülöp and Vadim N. Gladyshev and Mahdi Moqri and Marcel G. M. Olde Rikkert and Martin A. Picard},
year = {2024},
doi = {10.31219/osf.io/uf25z},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The EPMA Journal 2011
Open access · CC-BY
Personalized cardiac regeneration by stem cells–Hype or hope?
eScholarship (California Digital Library) 2019
Preprint · OA
Partial Reprogramming: A Shortcut to Rejuvenation
Journal of Pharmaceutical Research and Integrated Medical Sciences 2026
Open access · CC-BY
Hallmarks of Aging 2.0: Decoding the Molecular Drivers of Human Longevity – Senolytics Vs. Senomorphics as Strategies to Eliminate Senescent “Zombie” Cells
Journal of Clinical Investigation 2018
Open access · OA
Short telomere syndromes cause a primary T cell immunodeficiency
FEBS Letters 2019
Open access · OA
Mechanisms of cellular rejuvenation
2020
Citation only